Muna Therapeutics ApS
CVR 41142871 · Private limited company (ApS) · Active · Medium risk
Muna Therapeutics ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 1.9% over the next 12 months, which is 1.3 times the average for Danish companies. 6 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -120.3m and a net result of DKK -125.7m.
Bankruptcy risk for Muna Therapeutics ApS
1.3 × the average (1.41%) · higher risk than 82% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 41142871
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (6 years)
- Address
- Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 1.3m
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 6 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -38.7% |
| Current ratio | 152% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -60.6m | DKK -124.7m |
| Net profit | DKK -125.7m | DKK -174.8m |
| Equity | DKK -120.3m | DKK 6.1m |
| Total assets | DKK 311.1m | DKK 168.5m |
| Cash | DKK 250.2m | – |
| Short-term debt | DKK 181.5m | – |
| Avg. employees | 18 | – |
Latest annual report: Reporting class B · auditor's statement: Independent Auditor’s Report · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 153 | ||
| 1 Jan 2024 – 31 Dec 2024 | 147 | ||
| 1 Jan 2023 – 31 Dec 2023 | 149 | ||
| 1 Jan 2022 – 31 Dec 2022 | 179 | ||
| 1 Jan 2021 – 31 Dec 2021 | 159 | ||
| 22 Jan 2020 – 31 Dec 2020 | 146 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| Board | Henrijette Elsebeth Richter | Current | |
| Board | Rita Balice-Gordon | Current | |
| Board | Cillian King | Current | |
| Board | Laia Crespo-Martin | Current | |
| Board | Donald William Nicholson | Current | |
| Board | Eileen Elizabeth McGuire | Current | |
| Board | Camilla Petrycer Hansen | Current | |
| Board | Luc Madeleine Albert Dochez | Current | |
| Board | Michel Marcel A. Detheux | Current | |
| Board | Peder Søndergaard Madsen | ||
| Board | Anders Mørkeberg Hinsby | ||
| Board | Camilla Petrycer Hansen | ||
| Board | Simon Glerup Pedersen | ||
| Board | Morten Døssing | ||
| Board | Joachim Pold Vilstrup | ||
| Board | Stefan Lohmer | ||
| Board | Chiara Rossana Maria Liberati | ||
| Board | Luc Dochez | ||
| Board | Isaac Ciechanover | ||
| Board | Morten Døssing | ||
| Board | Reza Halse | ||
| Owner (5%) | Axxam S.p.A. | Current | |
| Owner (15%) | Droia GD SCSp | Current | |
| Owner (5%) | LSP Dementia Fund Coöperatieve UA | Current | |
| Owner (5%) | Sanofi Foreign Participations B.V. | Current | |
| Owner (5%) | Rita Balice-Gordon | Current | |
| Owner (15%) | Sofinnova Capital IX | Current | |
| Owner (15%) | Novo Holdings A/S | Current | |
| Owner (20%) | Camilla Gustafsen Consulting ApS | ||
| Owner (20%) | Peder Søndergaard Madsen Consulting ApS | ||
| Owner (20%) | Simon Glerup Consulting ApS | ||
| Owner (20%) | Joachim Vilstrup Holding ApS | ||
| Owner (20%) | S. Skeldal Holding ApS | ||
| Owner (15%) | Camilla Gustafsen Consulting ApS | ||
| Owner (15%) | Peder Søndergaard Madsen Consulting ApS | ||
| Owner (15%) | Simon Glerup Consulting ApS | ||
| Owner (10%) | WoB Holding ApS | ||
| Owner (15%) | Joachim Vilstrup Holding ApS | ||
| Owner (15%) | S. Skeldal Holding ApS | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (5%) | Camilla Gustafsen Consulting ApS | ||
| Owner (5%) | Peder Søndergaard Madsen Consulting ApS | ||
| Owner (5%) | Simon Glerup Consulting ApS | ||
| Owner (5%) | Joachim Vilstrup Holding ApS | ||
| Owner (5%) | S. Skeldal Holding ApS | ||
| Owner (20%) | Axxam S.p.A. | ||
| Owner (50%) | Novo Holdings A/S | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (33%) | Axxam S.p.A. | ||
| Owner (25%) | Axxam S.p.A. | ||
| Owner (25%) | Rita Balice-Gordon | ||
| Owner (15%) | Novo Holdings A/S | ||
| Owner (10%) | Rita Balice-Gordon | ||
| Owner (5%) | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | ||
| Owner (10%) | Sofinnova Capital IX | ||
| Owner (20%) | Novo Holdings A/S | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | BDO Holding VII, statsautoriseret revisionsaktieselskab | ||
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | Camilla Gustafsen Consulting ApS | Current | |
| Founder | Peder Søndergaard Madsen Consulting ApS | Current | |
| Founder | Simon Glerup Consulting ApS | Current | |
| Founder | Joachim Vilstrup Holding ApS | Current | |
| Founder | S. Skeldal Holding ApS | Current |
Address history (2 moves)
| Nordre Fasanvej 215, 2000 Frederiksberg | |
| Ole Maaløes Vej 3, 2200 København N | |
| Mejlgade 47, st. 2, 8000 Aarhus C |
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Hemab ApS Frederiksberg
- LactaPure IVS Frederiksberg
- SoftOx Solutions Denmark A/S Frederiksberg
- Guldstoev Pharma IVS Frederiksberg C
- Microembed Pharmaceuticals IVS Frederiksberg
Questions and answers about Muna Therapeutics ApS
Has Muna Therapeutics ApS gone bankrupt?
No, Muna Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Muna Therapeutics ApS?
Our model estimates a bankruptcy risk of 1.9% over the next 12 months (medium risk), which is 1.3 times the average for Danish companies.
Who is the auditor of Muna Therapeutics ApS?
Muna Therapeutics ApS most recently used EY Godkendt Revisionspartnerselskab.
When was Muna Therapeutics ApS founded?
Muna Therapeutics ApS was founded on 22 January 2020.
What is the equity of Muna Therapeutics ApS?
Equity was DKK -120.3m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.